Results for ipersensitivita translation from Maltese to English

ipersensitivita
hypersensitivity

mhux komuni: ipersensitivita`
uncommon: hypersensitivity

ipersensitivita` ghal mediċina(1)
drug hypersensitivity(1)

ipersensitivita u dizordni allerġiċi:
hypersensitivity and allergic disorders:

ipersensitivita`(inkluż anġjoedima u anafillassi)
hypersensitivity (including angioedema and anaphylaxis)

tista’ tikkawża reazzjoni ta’ ipersensitivita’.
a hypersensitivity reaction may occur.

neulasta għandu jitwaqqaf għal kollox f’pazjenti li jkollhom ipersensitivita klinikament sinjifikanti.
permanently discontinue neulasta in patients with clinically significant hypersensitivity.

m’għandekx tagħti ristempa lil pazjienti bi storja ta’ ipersensitivita għal pegfilgastrim jew filgastrim.
do not administer ristempa to patients with a history of hypersensitivity to pegfilgrastim or filgrastim.

m’għandekx tagħti neulasta lil pazjienti bi storja ta’ ipersensitivita g ħal pegfilgastrim jew filgastrim.
do not administer neulasta to patients with a history of hypersensitivity to pegfilgrastim or filgrastim.

f’kura għal tul ta’ żmien, il- frekwenza ta effetti avversi minħabba ipersensitivita ma żdietx.
over long term treatment, the frequency of hypersensitivity-related adverse events did not increase.

ipersensitivita`, li tista` tinkludi angjodema, edima fl-ilsien u edima fix- xofftejn
hypersensitivity, which may include angioedema, tongue oedema and lip oedema

aċċessjoni, tnaqqis fil- profondita` jew ir- rata tan- nifs, urtikarja, ipersensitivita`, ħsibijiet ta ’ suwiċidju
convulsion, decreased breathing depth or rate, hives, hypersensitivity, suicidal thoughts

fi studji kliniċi kbar ikkontrollati minn plaċebo, il-perċentaġġ ta’ pazjienti li kellhom esperjenza ta xi effett avvers ta’ ipersensitivita’ inkluz l-urtikarja, raxx u reazzjonijiet allerġiċi kien xi ftit għola fil- grupp ta raptiva (8%) milli fil-grupp ta plaċebo (7%). (ara sezzjoni 4.4).
in large placebo-controlled clinical studies, the percentage of patients experiencing an adverse event suggestive of hypersensitivity, including urticaria, rash and allergic reactions was slightly higher in the raptiva group (8%) than in the placebo group (7%). (see section 4.4).